Paternal Valproate Use and Neurodevelopmental Disorder and Congenital Malformation Risk in Offspring
In this cohort study, higher NDD risk was observed in offspring paternally exposed to valproate vs lamotrigine or levetiracetam, but no difference in CM risk was observed between the 2 exposure groups. However, these findings should be interpreted with caution due to the heterogeneity in the unadjusted estimates.
Authors
- Florent Richy
- Romina di Giuseppe (ORCID: https://orcid.org/0000-0002-5214-8897)
- Ana Cristina Santos (ORCID: https://orcid.org/0000-0002-2992-5299)
- Maria Roberta Cilio (ORCID: https://orcid.org/0000-0003-2481-8053)
- Marie‐Laure Kürzinger (ORCID: https://orcid.org/0000-0002-2606-776X)
- Sandrine Colas
- Juliette Longin
- Marte‐Helene Bjørk (ORCID: https://orcid.org/0000-0002-5745-1094)
- Alessandra Venerus (ORCID: https://orcid.org/0000-0002-2899-0806)
- Sigal Kaplan (ORCID: https://orcid.org/0000-0002-3352-8480)
- David Bigat
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- University of Liège (BE)
- Haukeland University Hospital (NO)
- IQVIA (United Kingdom) (GB)
- Sanofi (France) (FR)
- Teva Pharmaceuticals (Israel) (IL)
- IQ Solutions (US)
- Teva Pharmaceuticals (Czechia) (CZ)
- University of Bergen (NO)
- UCLouvain (BE)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.42581
- Citations
- 8
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 27.95